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Background: Autism spectrum disorders (ASD) are a group of neurodevelopmental disorders with high heritability.
Recent findings support a highly heterogeneous and complex genetic etiology including rare de novo and inherited
mutations or chromosomal rearrangements as well as double or multiple hits.
Methods: We performed whole-exome sequencing (WES) and blood cell transcriptome by RNAseq in a subset of
male patients with idiopathic ASD (n = 36) in order to identify causative genes, transcriptomic alterations, and
susceptibility variants.
Results: We detected likely monogenic causes in seven cases: five de novo (SCN2A, MED13L, KCNV1, CUL3, and
PTEN) and two inherited X-linked variants (MAOA and CDKL5). Transcriptomic analyses allowed the identification of
intronic causative mutations missed by the usual filtering of WES and revealed functional consequences of some
rare mutations. These included aberrant transcripts (PTEN, POLR3C), deregulated expression in 1.7% of mutated
genes (that is, SEMA6B, MECP2, ANK3, CREBBP), allele-specific expression (FUS, MTOR, TAF1C), and non-sense-mediated
decay (RIT1, ALG9). The analysis of rare inherited variants showed enrichment in relevant pathways such as the
PI3K-Akt signaling and the axon guidance.
Conclusions: Integrative analysis of WES and blood RNAseq data has proven to be an efficient strategy to identify
likely monogenic forms of ASD (19% in our cohort), as well as additional rare inherited mutations that can
contribute to ASD risk in a multifactorial manner. Blood transcriptomic data, besides validating 88% of expressed
variants, allowed the identification of missed intronic mutations and revealed functional correlations of genetic
variants, including changes in splicing, expression levels, and allelic expression.
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Autism spectrum disorders (ASD) [OMIM 209850] are
defined as a group of neurobehavioral syndromes charac-
terized by deficits in social interaction, impaired commu-
nication skills and restricted, stereotypical and ritualized
patterns of interests and behavior, typically appearing be-
fore the age of 3. Throughout the last decades, the preva-
lence of ASD has risen from the historically estimated* Correspondence: luis.perez@upf.edu; ivon.cusco@upf.edu
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(2008) [1-3] with a ratio four times higher in males than
females [4]. It is still debated how much of this increase is
related to diagnostic improvements, raised awareness to-
wards ASD, or emerging environmental factors [5,6]. ASD
are among the most heritable neuropsychiatric disorders,
given that concordance rates in monozygotic twins are
90% and siblings have an approximately 50-fold increased
risk of ASD. ASD are found in association with comorbid
genetic conditions in 10% of cases and are considered
complex multifactorial disorders involving multiple genesntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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30% of the cases and remains unknown for most patients.
The technological improvements of the last decade have
lead to tremendous advances in understanding the genetic
basis of ASD, revealing a high degree of genetic heterogen-
eity. Clinical application of molecular karyotyping has
shown that 5% to 10% of patients carry chromosomal rear-
rangements and that the burden of rare and de novo
smaller copy number variants (CNVs) is higher among
ASD patients than controls. However, since many of these
variants show incomplete penetrance and variable pheno-
typic expression, the best model to explain most ASD cases
would be oligogenic with a probable environmental contri-
bution. Until now, most genomic studies on ASD using
next-generation sequencing (NGS) have focused on coding
regions and have analyzed trios in an effort to identify de
novo mutations [9-14]. Only a few studies investigated rare
inherited variation [15-18]. The reported data suggest a
contribution of de novo disruptive mutations in the genetic
etiology of ASD, with hundreds of genes implicated and
only a few of them recurrently mutated in unrelated cases
(CHD8 [MIM 610528], DYRK1A [MIM 600855], GRIN2B
[MIM 138252], KATNAL2 [MIM 614697], POGZ [MIM
614787], and SCN2A [MIM 182390]). Besides de novo dis-
ruptive mutations, comparison of rates of rare variation
across the whole genome in cases versus controls have
yielded no significant associations. These findings support
previous hypothesis which suggested that a large number
of genes confer risk to ASD and reinforce the idea that
much larger cohorts will be necessary to carry out this type
of analyses [19]. The identification of new genes involved
in ASD will eventually lead to the definition of common ef-
fects of genetic variants and possibly ASD biomarkers and
biological signatures. Biology system tools such as inter-
action networks are important to detect common
deregulated pathways and expression networks implicated
in the disease.
An additional approach to identify genetic variants asso-
ciated with a phenotype and to understand the biological
effects resulting from rare genetic variation could be de-
rived from observing the transcriptomic consequences of
genetic variation [20]. To this end, we have analyzed 36
Spanish male patients with idiopathic ASD by whole-
exome sequencing (WES) to define causative or suscepti-
bility variants for ASD and their transcriptomic conse-
quences by RNAseq. In addition to the identification of
likely monogenic cases, we also studied the accumulation




We studied 36 unrelated males with a diagnosis of idio-
pathic ASD selected from a Spanish cohort of 324 patients.All cases except two were sporadic. All patients had a con-
firmed diagnosis of one of the categories of ASD listed in
the Diagnosis and Statistical Manual of Mental Diseases IV
(DSM-IV), categorized according to the Spanish version of
ADI-R (Autism Diagnostic Interview-Revised), and the
Wechsler Intelligence Scale for Children or Wechsler
Adult Intelligence Scale. All patients had an extensive
clinical and molecular evaluation including fragile X
testing and molecular karyotype (either BAC, oligo, or
SNP array) with normal results. The study was approved
by the Clinical Research Ethics Committee of the centers
involved (CEIC-Parc Salut Mar), and informed consent for
participation was obtained from the parents or legal
caregivers. Blood samples were obtained, and genomic
DNA was extracted by the salting out method using the
Puregene® DNA Purification Kit (Gentra Systems, Big
Lake, MN, USA). Parental and familial samples were
obtained from the available relatives who gave informed
consent.
Whole-exome capture and sequencing
The exome portion of the genome was enriched using
NimbleGen EZ Exome V2.0 capture kit (Roche Applied
Science, Madison, WI, USA). Gene and exon annota-
tions for SeqCap EZ Human Exome Library came from
RefSeq (Jan 2010), CCDS (Sept 2009), and miRBase
(v.14, September 2009). A total of approximately 30,000
coding genes (approximately 300,000 exons, total size
36.5 Mb) were targeted by the design, and a total of 44.1
Mb were covered by the probes. Final libraries were then
sequenced on an ABI Solid 4 platform (Life Technologies,
Carlsbad, CA, USA). Single-end sequences were obtained
with a read length of 50 bp.
Variant calling, annotation, and prioritization
A pipeline for data alignment using BFAST [21] and
GATK [22] algorithms was applied to the sequencing
data following standard parameters. Briefly, sequences
were aligned to the latest version of the human genome
(hg19), PCR duplicates were marked and removed, and
quality scores of alignments were recalibrated. Single
nucleotide variants (SNV) and indel calls were only
considered if positions had a depth of coverage of at
least 10×, and heterozygous positions were only called
when a minimum of 20% of the reads showed the vari-
ant (AB between 0.2 and 0.8). In order to minimize
technical artifacts, we removed variants that appeared
in more than two samples, even if they were present in
a single read or had an AB ratio lower than 0.2. Anno-
tation of variants was performed using ANNOVAR
(http://www.openbioinformatics.org/annovar/), taking into
account the variant frequency in control databases:
dbSNP135 (http://www.ncbi.nlm.nih.gov/SNP/), Exome
Variant Server (EVS) (http://evs.gs.washington.edu/EVS/),
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ture of the changes was assessed by PolyPhen and Condel
(http://bg.upf.edu/fannsdb/) protein effect prediction algo-
rithms [23]. To distinguish the putative disease-causing
variants, we established the following criteria: (1) we se-
lected only non-synonymous variants; (2) under a domin-
ant model, we excluded variants previously described in
the general population (dbSNP135, EVS, 1000 Genomes
(http://browser.1000genomes.org) and Spanish controls);
(3) under a recessive model, we removed variants with a
minor allele frequency (MAF) >0.002 and only considered
genes with homozygous or compound heterozygous muta-
tions; (4) we discarded variants present in loss of function
tolerant genes as previously described [24]; and (5) we
manually inspected recurrent variants and indel calls to
exclude false positives using Integrative Genomics Viewer
(IGV) [25].
We used the XHMM algorithm to call CNVs, based on
measurement of the read depth per target region (GATK).
We followed the standard steps as described in the online
tutorial. We applied the same filters previously described
[26]: XHMM quality score (SQ) ≥65, exons spanned ≥3,
and estimated CNV length ≥1kB. We focused our analysis
on rare CNVs, so we excluded CNVs overlapping with
polymorphic variants reported in Database of Genomic
Variants (DGV) (http://dgv.tcag.ca/dgv/app/home).
Validation
We used Sequenom genotyping (iPLEX Gold platform,
San Diego, CA, USA) and Sanger sequencing by capillary
electrophoresis (ABI PRISM 7900HT, Applied Biosystems,
Foster City, CA, USA) to perform validation and segre-
gation studies. To genotype the selected variants, we
designed primers (PRIMER 3 application) (http://www.bio
informatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) and
used standard PCR conditions. For CNV validation, we
used multiple ligation probe amplification (MLPA) with
custom probes in the target region. MLPA reactions were
carried out under standard conditions. The relative peak
height method was used to determine the copy number
status. We analyzed samples from the proband and
both parents as well as from other relatives when
available.
Paternity testing
We performed microsatellite genotyping of trios to cor-
roborate paternity on patients with de novo mutations.
We selected highly heterozygous microsatellites markers
randomly distributed in different autosomal chromo-
somes. PCR products were amplified under standard
conditions, and fragments were separated and analyzed
by high-resolution electrophoresis using GeneMapper
software (ABI 3100, Applied Biosystems, Foster City,
CA, USA).X-chromosome inactivation analysis
To determine the X-chromosome inactivation pattern
(XCI), we examined the differential methylation state of
nearby HpaII sites of the polymorphic CAG repeat in
exon 1 of the human androgen receptor gene (AR [MIM
313700]) located at Xq13. Following digestion with
methylation sensitive restriction endonuclease HpaII, the
region was amplified by PCR with a FAM labeled for-
ward primer [27,28]. The digested and not digested PCR
products were analyzed in an ABI PRISM 3100 Genetic
Analyzer. For quantitative analysis, trace data were re-
trieved using the accompanying software (GeneMapper,
Applied Biosystems, Foster City, CA, USA). The degree
of XCI skewing was calculated as the fractional peak
height ratio (expressed as %) for the more strongly amp-
lified allele. XCI was considered significantly skewed if
the ratio exceeded 90:10.
Transcriptome sequencing
Peripheral mononuclear cells (PBMCs) from whole
blood of 36 studied ASD patients were isolated using a
ficoll density gradient (Lymphoprep™, STEMCELL Tech-
nologies, Vancouver, British Columbia, Canada). Total
RNA was extracted using Trizol (Life Technologies,
Carlsbad, CA, USA) following a standard protocol. The
quality and yield of the isolated RNA was assessed using
a NanoDrop8000 Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) and Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA, USA).
Transcriptome sequencing was performed on a HiSeq
2000. Paired-end sequences were obtained at a read
length of 100 bp with 57,792,576 mean read pairs per
sample. Sequences were aligned to the NCBI build 37
human genome reference using TopHat [29] and Bowtie
[30] to map the inter-exon splice junctions. Cufflinks [31]
and htseqcount [32] were used to estimate the expression
of the transcripts (FPKM - fragment per kilobase of tran-
script per million fragments mapped- and read counts).
We used the ComBat algorithm (http://www.bu.edu/jlab/
wp-assets/ComBat/Abstract.html) (package sva R) to re-
move batch effect and to obtain the z-score of expressed
genes.
Allele-specific expression analysis
In order to study extreme imbalances of allelic expres-
sion, either allele-specific or preferential expression, we
selected heterozygous SNPs (dbSNP135) identified by
WES in each patient with a minimum depth of coverage
of 15 and an AB ratio between 0.3 and 0.7. SNPs in
known segmental duplications or pseudogenes according
to UCSC hg19 (http://genome.ucsc.edu/cgi-bin/hgGate-
way) ‘Segmental Dups’ and ‘Retroposed Genes’ tracks
were excluded from the analyses. We then extracted the
number of RNAseq reads mapped to each position and
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classified each SNP expression according to its AB ratio,
being biallelic when the AB ratio was between 0.1 and
0.9 and monoallelic when predominantly the reference
or alternative allele were expressed (AB > 0.9 or <0.1).
When all SNPs of a gene were monoallelic, we classified
the gene as having monoallelic expression, whereas
genes with biallelic SNPs were considered to have biallelic
expression.
Isoform-splicing analysis
The aligned reads were processed by Cufflinks, using a sup-
plied reference annotation (Homo_sapiens.GRCh37.68.gtf)
to guide RABT assembly. Assembled transcripts were then
analyzed by Cuffcompare to compare isoforms across all
samples. We then selected novel isoforms (defined by
Cufflinks by class code j) with an expression >2 FPKM and
matched them to rare variants found by exome sequencing
in the same patient.
RNA editing analysis
We first applied stringent filtering criteria to remove
RNAseq false positive calls (DP > 10, SB ≤ 0.1, HRun < 8,
ReadposRankSum ≥ 2.0, BaseQRankSum ≥ 2) and then
annotated depth of coverage of the same positions accord-
ing to exome sequencing. We selected only positions with
a depth of coverage of at least 15× and that were not
called by exome sequencing, excluding all variants de-
scribed in control databases (dbSNP135, Exome Variant
Server) and those present in another sample. We
manually revised the remaining variants to discard false
positive calls.Figure 1 Workflow of the Omics approach used to define the likely p
the studied ASD cohort.Pathway enrichment analysis
To identify common deregulated mechanisms affected
by rare genetic variants, we performed pathway enrich-
ment analyses using the publicly available Consensus-
PathDB database (CPDB) (http://cpdb.molgen.mpg.de/).
CPDB incorporates interaction data from different cat-
egories including metabolic and signaling reactions, phys-
ical protein and genetic interactions, or gene regulatory
interactions. Statistical analyses were performed using the
CPDB overrepresentation analysis option, with four cat-
egories of predefined genes (network neighborhood-based,
pathways-based, Gene Ontology-based and protein
complex-based gene sets). For each of the predefined sets,
a P-value was calculated according to the hypergeometric
test based on the number of physical entities present in
both the predefined set and user-specified list of physical
entities. For pathway-based sets, we used the default P-
value threshold of 0.01. We used the default gene back-
ground defined by CPDB as the number of entities that
are annotated within the category of the provided gene.
We then compared overrepresented pathways among rare
WES variants in ASD samples with respect to 55 Spanish
non-ASD samples.
Results
In order to perform the integrative analysis of next-
generation sequencing data, we followed the workflow
shown in Figure 1.
WES general overview
Overall, a mean depth of coverage of 40× was obtained
and an average of 26,605 variants per sample was observed.athogenic genetic variants and transcriptomic consequences in
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shift, or splice site rare variants (MAF dominant = 0; reces-
sive <0.002), we selected a total of 2,626 calls, with an
average of 73 rare events per patient (Figure 1). We classi-
fied the variants into missense and loss of function variants
(LoF), a category which included splicing, non-sense, and
frameshift mutations. Most rare variants were missense
(91%), while six per sample on average (9%) were LoF
(Additional file 1: Figure S1). The 2,626 rare variants were
distributed in 2,205 genes, most of them carrying just one
mutation, although some accumulated a high number of
rare variants, with extreme cases such as MUC16 (MIM
606154) and TTN (MIM 188840) with 8 and 17 differ-
ent mutations, respectively.
We considered likely pathogenic mutations all LoF vari-
ants, predicted damaging variants on the X chromosome
or in autosomal candidate genes (according to the two
main ASD databases, SFARI and AUTkB, see Additional
file 2: Table S1) [33,34] and variants which involved a de-
tectable change in the gene expression. To discriminate
putative ASD pathogenic genes from non-related loci
which accumulate LoF without any pathological conse-
quence [24], we analyzed the distribution of this type
of variants in the population with European ancestry
described in the EVS (n ~ 4,300), which contains exome
sequencing data from individuals with unrelated disorders.
We only considered as candidates the LoF variants that
were found in genes with no LoF mutations in the general
population. We finally selected 121 variants, with an
average of 3 per patient. All novel variants absent in
dbSNP137 (n = 109) were validated by Sequenom and/or
Sanger sequencing, and segregation studies were per-
formed using parental and other relatives’ samples when
available (Additional file 2: Table S2).
Autosomal variants
We studied the inheritance of 103 likely damaging vari-
ants (70 LoF and 33 missense) in candidate autosomal
genes using parental samples. Only 5/103 rare variants
(4.8%) were de novo, and the remaining (95.2%) were
inherited from unaffected parents. De novo LoF muta-
tions were detected in SCN2A (p.R583X), MED13L
[MIM 608771] (c.1708_1709delAG), KCNV1 [MIM
608164] (c.1391_1392delAT), and ADIPOR2 [MIM
607946] (p.R31X) in four different patients. Three of de
novo LoF mutations are probably pathogenic, since they
are predicted to result in truncated proteins. However,
the de novo variant in ADIPOR2 found in a familial
case (ASD_16) was not present in the affected sibling,
excluding it as main ASD cause in this family although
it could contribute as a modifier of the phenotype [35].
Additionally, we detected a de novo missense mutation
affecting a highly conserved residue in CUL3 [MIM
603136] (p.H719R). Paternity was confirmed in allcases. Notably, none of these genes present a LoF variant
in the general population. Detailed information about the
phenotype of these patients is shown in Table 1.
De novo non-sense SCN2A mutations have been
already described in several cases of ASD [10,36-38].
The mutation we report is found in patient ASD_5; it re-
sults in a stop codon located after the first transmem-
brane domain, leading to a truncated protein with only
one of the four transmembrane domains. The two base-
pair frameshift deletion in MED13L in patient ASD_11
generates a premature stop codon and a truncated pro-
tein lacking its main part. The frameshift mutation in
KCNV1 in patient ASD_14 produces a stop codon
shortly after, resulting in a prematurely truncated pro-
tein and abolishing the last cytoplasmatic domain.
CUL3, mutated in ASD_7, has already been reported as
ASD candidate, given that two de novo non-sense muta-
tions were identified in previous work, a result that is
highly unlikely by chance [11,39].
All remaining variants were inherited from unaffected
parents, suggesting either incomplete penetrance of
these mutations or a contribution as an additive effect in
those patients (Additional file 2: Table S2).
X-linked variants
We validated and performed segregation studies on all
X-linked variants that had not been previously reported
or were found in candidate genes. We extended the
study to the available healthy male family members to
discard variants that did not segregate with the phenotype
(Additional file 2: Table S3).
We found two X-linked mutations in MAOA (MIM
309850) and CDKL5 (MIM 300203). A splicing mutation
(c.1438-2A > G) in MAOA was detected in the autistic
proband (ASD_16) and later also in his brother diag-
nosed with pervasive developmental disorder not other-
wise specified (PDD-NOS) (Table 1). The mother
(mutation carrier) and maternal grandmother presented
with a depressive and bipolar disorder, respectively. Un-
fortunately, no DNA was available from the grand-
mother to analyze the presence of the variant. The
mutation led to aberrant splicing through the use of a
cryptic splice site within intron 15 of MAOA that was
confirmed by RT-PCR of blood mRNA from the patients
(Additional file 1: Figure S2). We also determined the
levels of catecholamines and related metabolites in urine
of these patients and their mother. These studies showed
altered levels of several neurotransmitters in both
affected brothers [increased serotonine (2×), normeta-
nephrine (2.4×), and 5-HIAA (0.45×)] and very mild in
their mother (Additional file 2: Table S4), confirming the
alteration of the monoamine metabolism.
A missense variant affecting a highly conserved residue
(p.P647L) in the CDKL5 gene was also found in patient





















ASD_1 1992 Severe AUT No No No Obesity CDKL5 (p. P647L)
ASD_2 1995 Severe PDD-NOS No No No Hypermetropia Agrin in postsynaptic
differentiation
Elastic fiber formation









ASD_3 1993 Mild AUT Yes No No
ASD_4 1995 Mild AUT Yes No No
ASD_5 1997 Moderate AUT No No Yes ADHD SCN2A (p.R583X)
ASD_6 1998 Mild AUT No No Yes




ASD_8 1991 None AUT No No Yes Integrin cell surface
interactions
ASD_9 2000 Moderate AUT No No No
ASD_10 2000 Severe AUT No No No






ASD_12 2002 Moderate AUT No Yes No ADHD








ASD_14 2000 Severe AUT No No No ADHD KCNV1
(c.1391_1392delAT)
ASD_15 2001 Mild AUT Yes Yes Yes
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ASD_21 1997 Severe AUT No Yes No Sleep disturbance
ASD_22 2000 Moderate AUT No No No
ASD_23 2005 None AUT No No NO
ASD_24 2000 Severe AUT Yes No No ADHD
ASD_25 2002 Mild AUT No Yes Yes
ASD_26 2000 Mild AUT Yes No No PI3K-Akt signaling
pathway
ASD_27 2005 AUT No No Trimethylaminuria Beta1 integrin cell
surface interactions

























ASD_29 1999 Severe AUT No No No Huntington’s disease
ASD_30 1997 Severe AUT Yes No No Termination of
O-glycan biosynthesis
ASD_31 2008 None AUT No No Yes
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Table 1 Summary of the phenotypic features of ASD patients and relevant findings of the study (Continued)
Striated muscle
contraction
ASD_32 2004 Mild AUT No No Yes
















ASD_36 1999 Severe AUT No No No Macrocephaly PTEN
(c.239-21G > C)
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inherited from the mother and also present in the healthy
sister but not in two healthy uncles. CDKL5 is a member
of the Ser/Thr protein kinase family and encodes a phos-
phorylated protein with protein kinase activity. Mutations
in this gene have been associated with X-linked infantile
spasm (ISSX) and atypical Rett syndrome (RTT) [40-43].
We also carried out X chromosome inactivation (XCI)
analyses on blood cell DNA from all 36 mothers of the
probands, as an additional tool to predict putative
pathogenicity of X-linked mutations. Six mothers were
non-informative, 25 had a random XCI, and 5 showed a
skewed XCI with ratios >90%. Among the XCI skewed
mothers, only two presented rare variants in the X
chromosome, being one also detected in a healthy uncle
and the other inactivated preferentially the non-
transmitted allele. In the CDKL5 mutation carriers, the
XCI study was not informative in the mother but the
proband’s sister showed a selective inactivation of the
maternally inherited mutated allele.
Recurrently mutated genes in ASD
We studied in detail the presence of recurrently mutated
genes and the functional consequences resulting from
the accumulation of rare genetic variants to identify
common mechanisms involved in ASD etiology.
Since most putative pathogenic variants detected were
inherited, we focused on genes mutated in more than
one case of our ASD cohort. We found a total of 297 re-
currently mutated genes, although most of them also
showed a significant load of rare variants in the generalpopulation (EVS data). A total of 15 genes lacking LoF
mutations in publicly available data from EVS were mu-
tated with at least one LoF in more than one ASD case
of our cohort (Additional file 2: Table S5). The list in-
cludes two genes with de novo variants in a patient and
a missense mutation in the second patient (SCN2A and
MED13L). These variants cannot be fully penetrant muta-
tions since they were inherited from healthy progenitors,
but might behave as susceptibility factors in multifactorial
or multiple-hit models. A proper association study with
much larger sample size would be required to draw more
clear conclusions about the pathogenicity of the recur-
rently mutated genes observed in this series.
Common functional pathways affected by inherited rare
mutations in ASD
Previous studies suggest that, in addition to the relatively
rare de novo and Mendelian forms, the etiology of ASD is
mostly multifactorial with multiple genetic hits, mainly rare
genetic variants in a few of hundreds of candidate genes
[10,11,44]. To further define the potential pathogenic con-
tribution to ASD of the inherited variants and identify com-
mon functional consequences, we conducted pathway
enrichment analyses for each individual of our cohort ex-
cluding those with presumably monogenic forms (ASD_1,
ASD_5, ASD_7, ASD_11, ASD_14, ASD_16, and ASD_36)
(n = 29) compared with 55 Spanish non-ASD controls.
Using CPDB [45], we found 29 pathways overrepresented
in ASD, 21 of them ASD-exclusive and absent in controls
(Table 1). Interestingly, some of these pathways have also
been previously related with the ASD phenotype, such as
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checked if the genes involved in monogenic cases are also
involved in overrepresented pathways. The results show
that three of the de novomutated genes are part of overrep-
resented pathways. SCN2A is involved in Axon Guidance
and L1CAM interaction pathways and PTEN is part of the
PI3K-AKt and PDGF signaling pathways. These data under-
score the role of those pathways in the pathogenesis of the
ASD.
Rare CNVs in ASD samples
Although all patients had a previous molecular karyo-
type (either BAC, oligo, or SNP array), we analyzed
copy number variants from exome data to identify
small rare rearrangements that could have been previ-
ously missed. Using the XHMM algorithm and appro-
priate filtering, we detected a total of 11 rare CNVs
(3 deletions and 8 duplications), ranging from 8.2 to
254 Kb. All were validated by MLPA and segregation
studies showed that all were inherited from an unaffected
progenitor (Additional file 2: Table S6). One of these
inherited duplications (patient ASD_9) at chr14q24.2 in-
cludes three genes (DCAF4, RBM25 [MIM 612427],
ZFYVE1 [MIM 605471]) and partially disrupts two genes
(PSEN1 [MIM 104311] and DPF3 [MIM 601672]). PSEN1
encodes a protein that regulates the processing of amyloid
precursor protein (APP) and is mutated in familial forms
of Alzheimer’s disease while DPF3 function is associated
with the BAF chromatin remodeling complex to promote
transcription during development [49]. In addition, we de-
tected two unrelated ASD individuals carrying a duplica-
tion of the X-Y pseudoautosomal ASMT [MIM 300015,
402500] previously associated with autism phenotype and
sleep disturbance [50-52].
Transcriptomic alterations in blood mRNA of ASD
Good-quality blood transcriptome by RNAseq was avail-
able from 32 patients. Up to 64% of protein coding genes
(14,114 of 22,057, according to Ensembl) were expressed
at >0.3 FPKM, which is considered a robust threshold of
gene expression [53]. No relevant differential transcrip-
tomic pattern was evident in any group of samples by
principal component analysis. We also compared individ-
ual samples against the rest in order to search for individ-
ual patterns of aberrant expression. The detectable
variable genes per patient were unrelated and did not re-
sult in a common biological signature.
The integrative study of WES and RNAseq was limited
to the almost 1/3 (30%) of the positions identified as rare
variants in exome data that had a depth of coverage >10×
in RNAseq, the established threshold for comparison. Out
of those variants, 88% were also concordantly detected by
RNAseq, showing high correlation between the two
techniques and demonstrating the calling robustness.mRNA expression consequences of rare variation
A total of 30 rare variants (1.7% of all expressed) corre-
lated with significant quantitative alterations in expres-
sion values of the same gene. All these variants were
inherited from healthy progenitors (Additional file 2:
Table S7). Among them, 6 were associated with de-
creased expression (z-score values ≤2), whereas 24 were
associated with overexpression (z-score values >2.5).
Two rare mutations in SEMA6B [MIM 608873] corre-
lated with SEMA6B overexpression in two different sam-
ples (ASD_29 and ASD_33, Figure 2). Interestingly,
ASD_29 carried two additional inherited candidate mis-
sense mutations in ANK3 [MIM 600465] and CREBBP
[MIM 600140], which also correlated with overexpres-
sion of the mutated genes (Figure 2). Whereas the
CREBBP variant was maternally inherited, the other two
were inherited from the father, who committed suicide.
We also detected a missense mutation (c.C1198T; p.P400S)
previously described as a rare SNP in the MECP2 [MIM
300005] that correlated with higher expression of the gene
(z-score = 2.16) (Additional file 2: Table S7).
We also evaluated the expression changes of the 22
genes contained in the 11 rare CNVs detected in ASD pa-
tients. Only eight genes were expressed in blood at >0.3
FPKM, but we did not detect any significant outlier in ex-
pression (z-score values ≤2 or >2.5). However, a global
analysis comparing z-score values between genes con-
tained in all detectable deletions and duplications (a total
of 26 expressed genes contained in any CNV), showed a
tendency for higher expression values for duplications
(mean z-score = 0.43) compared to deletions (mean z-
score = −0.39) (Additional file 1: Figure S3). Additionally,
we detected 10 inherited rare LoF variants resulting in a
premature stop codon associated with monoallelic expres-
sion of the wild-type allele, suggesting non-sense mediated
mRNA decay (Additional file 2: Table S8).
We also searched for possible mRNA editing events in
transcriptome data. After strict filtering process and man-
ual curation of the variants in IGV, we did not detect any
alteration indicative of mRNA editing. All mismatches be-
tween WES and RNAseq were either false negative WES
calls or RNA sequencing errors located in the last position
of the read or in a homopolymer region.
Isoform-splicing analysis
RNAseq technology offers the opportunity to identify not
only quantitative but also qualitative changes, including
novel isoform identification and accurate detection of
biased allele expression, in comparison to previous
technologies such as expression microarrays.
Isoform analysis by Cufflinks showed two aberrant
transcripts due to rare genetic variants. The first was
found in the PTEN and led to the insertion of an in-
tronic fragment and the incorporation of six new amino
Figure 2 Quantitative changes in expression associated with rare variants. (A) Familial pedigree showing segregation of rare mutations.
(B) Boxplot showing the distribution of expression values and expression outliers corresponding to the patients with rare mutations (in red).
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in close proximity to a deep intronic variant (c.239-
21G > C) that generates a cryptic splice site. Segregation
studies showed that it was de novo (Figure 3) and only
present in patient ASD_36. The second aberrant tran-
script was found in POLR3C and retains an intron that
generates a premature stop codon (ASD_2). The aberrant
transcript is caused by a mutation that disrupts a splicing
donor site (c.104 + 1G >A) inherited from the healthy
father.
Allele-specific expression
To search for extreme imbalances of allelic expression
or allele-specific expression, we studied 4,733 well-
covered genes with at least one heterozygous SNP not
located in a known segmental duplication or a pseudo-
gene. We found 4,426 genes (93%) with biallelic and 81
(2%) with monoallelic expression in all informative sam-
ples, while the expression was not homogenous among
samples for the remaining 226 genes (5%). Only three
genes with consistent monoallelic expression in all sam-
ples (SNRPN [MIM 182279], ZDBF2, and ZNF597
[MIM 614685]) are known to be imprinted. On the
other hand, we identified seven known imprinted genes
with biallelic expression in blood, two of them previ-
ously reported (NAA60 [MIM 614246] and ZFAT [MIM
610931]) [54-56]. Regarding individual differences, we
detected 78 genes with monoallelic expression in a sin-
gle patient but biallelic in the remaining (at least five in-
formative samples) excluding genes with biased
expression (AB ratio >0.8 or <0.2) in at least one sample
(Additional file 1: Figure S4). We did not found any indi-
vidual allelic imbalance in the opposite directionsuggestive of loss of imprinting (Additional file 2: Table
S9). Nine of the identified genes were previously de-
scribed to have monoallelic expression in control sam-
ples [57-59]. The allelic expression imbalance was found
in 26 of 32 samples, affecting between one and eight dif-
ferent genes with no regional clusters. None of these al-
lelic expression imbalances were apparently related to
cis-effects of the rare mutations or CNVs identified by
WES. Interestingly, some of the altered genes have been
associated to disease, such as MTOR [MIM 601231],
FUS [MIM 137070], and TAF1C [MIM 604905].
Discussion
Autism spectrum disorders are a group of heteroge-
neous disorders with a strong genetic component but
a complex genetic architecture. This complexity
makes genetic diagnosis challenging, with a current
diagnostic yield ranging from 15% to 30% [60,61]. Un-
biased genome-wide molecular tools such as NGS,
with a steadily lowering cost, have a proven efficacy,
although they produce genetic and genomic informa-
tion that cannot be properly interpreted yet. Here, we
used WES and blood transcriptome by RNAseq in a
selected group of males with idiopathic ASD to detect
putative causal genetic variants of this complex dis-
ease. Segregation and recurrence analyses along with
expression studies were used to better discriminate
putatively pathogenic variants from innocuous rare
variation.
WES identified several cases with likely monogenic
forms of ASD, including four patients with de novo
variants in strong candidate autosomal genes (11%)
and two patients with inherited X-linked mutations
Figure 3 Segregation analysis by Sanger sequencing and Integrative Genomics Viewer (IGV) pileups in two trios. (A) de novo mutation
(c.239-21G > C) found in the PTEN gene by exome sequencing and the aberrant transcript detected by transcriptome sequencing. (B) Paternal
inherited mutation that disrupts a splicing donor site in POLR3C gene (c.104 + 1G > A) causing retention of an intron.
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ome sequencing, our detection rate of monogenic
cases may be underestimated. Autosomal LoF muta-
tions were identified in SCN2A, MED13L, and
KCNV1. SCN2A is one of the few genes found recur-
rently mutated in unrelated patients with ASD and
intellectual disability, which is unlikely to occur by
chance [10,36,37,62]. MED13L was previously associ-
ated with intellectual disability and heart defects, and
a de novo splicing mutation was described in an autis-
tic patient [13,63]. Recently, de novo deletions affect-
ing coding regions of MED13L were found in two
girls presenting a phenotype very similar to the pa-
tient we report here, including facial dysmorphism,
hypotonia, and development delay, along with ASD[64]. Our findings are consistent with a role of
MED13L in neurodevelopmental disorders. The third
de novo and likely pathogenic variant affected
KCNV1, coding for a potassium channel subunit
mainly expressed in the brain and involved in the
regulation of two other potassium channels (KCNB1
and KCNB2). Defects in voltage-gated potassium
channels have been associated with a variety of neuro-
psychiatric disorders, including bipolar disorder,
schizophrenia, and ASD [12,65-67]. Therefore, our
data suggest a role for potassium voltage-gated chan-
nels in the etiology of ASD. Finally, we detected a de
novo missense mutation in the CUL3, which is other
of the few recurrently de novo mutated genes in ASD
patients [11,39].
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ations in two genes (MAOA and CDKL5) previously as-
sociated with ASD and intellectual disability. We found
a splicing mutation in MAOA in a multiplex family
with and X-linked pattern of inheritance, with two af-
fected male siblings and a maternal history of psychi-
atric disease. MAOA encodes the protein monoamine
oxidase A, which degrades amine neurotransmitters
such as dopamine, norepinephrine, and serotonin [68].
Both affected siblings had consistent biochemical alter-
ations of the catecholamine pathway, very mild in their
carrier mother, then supporting the pathogenicity of
the mutation. A MAOA truncating mutation was first
described in a Dutch family in 1993, and recently, a
second loss of function mutation was found in a family
segregating ASD and behavioral problems [69,70]. Our
work further strengthens the relation between MAOA and
ASD. The other X-linked mutation affected a highly con-
served amino acid in CDKL5 and is predicted to be dele-
terious by different algorithms [71,72]. It was inherited
from the healthy mother and also detected in the un-
affected sister, who preferentially inactivated the mutated
allele. Mutations in CKDL5 were reported in X-linked in-
fantile spasms syndrome (ISSX) [MIM 308350], atypical
Rett syndrome (RTT) [MIM 312750], and Angelman
syndrome-like [MIM 105830] [40-42,73,74]. Since the
phenotype of our patient is less severe than the one de-
scribed in males with CDKL5 mutations, it is possible that
the missense variant found in this patient is a hypo-
morphic allele with a milder effect. The biased X inactiva-
tion documented in the sister’s proband could act as a
protective factor in females explaining their unaffected
status.
While the definition of the potential pathogenicity
for ASD mutations could be relatively straightforward
in de novo and Mendelian cases assuming full pene-
trance, a greater challenge is the classification of
putatively pathogenic heterozygous mutations and re-
arrangements inherited from unaffected parents.
These variants, presumably with incomplete pene-
trance and variable expression, are thought to contrib-
ute to disease risk in an oligogenic model with
probable environmental contribution. One of the most
common criteria to define potential pathogenicity is
the recurrence of mutations in the same gene in unre-
lated patients. In our small cohort, we detected two
additional patients with rare inherited missense muta-
tions in genes with de novo LoF mutations in other
cases (SCN2A and MED13L), suggesting that the inher-
ited mutations could also be contributing to the dis-
ease. While amorphic alleles might be highly penetrant,
hypomorphic missense mutations might have a milder
effect just increasing the global burden of risk for ASD.
Moreover, the study of common functional consequencesof rare variation pointed towards a set of relevant path-
ways only overrepresented in ASD patients. Among these,
there were the PI3K/Akt signaling and the axon guidance
which were previously associated to ASD by linkage
studies, rare CNVs, genomic mutations, and comorbid
ASD conditions [45-48].
Using CNV detection tools on WES data, we identi-
fied small rearrangements that were missed by previ-
ous molecular karyotype in eight cases, all of them
inherited from unaffected progenitors. Some of these
rare CNVs could also contribute to the disease in a
multiple-hit model, such as the duplications found in
ASMT as previously proposed [50-52]. Although we
did not observe a significant effect on expression in
the individual analysis of these rare CNVs, a global
analysis showed a tendency for higher expression of
genes in duplication type CNVs compared to those in
deletions, as expected and described for other ASD-
related rearrangements [20,75].
The incorporation of the peripheral blood transcrip-
tomic data provided an important additive value to the
identification of molecular biomarkers of ASD, leading
to identification of additional mutations and transcrip-
tional consequences. Despite that blood is not the
ideal target tissue to study ASD, it is commonly used
in neurodevelopmental disorders since it can be easily
available for diagnostic testing [76]. In our study, ap-
proximately 30% of the rare variants were sufficiently
expressed in blood, and 88% of these had a concordant
calling in both techniques. By isoform analysis, we
found an aberrant transcript in PTEN, due to a de
novo intronic mutation that activates a cryptic splice
site. The patient (ASD_36) presents macrocephaly, a
feature that is consistently found in ASD patients with
mutations in this gene (MIM 605309). Thus, tran-
scriptome sequencing of blood cells was essential to
achieve a diagnosis in an additional patient, reaching a
final diagnosis yield of 19%. Moreover, the integrative ap-
proach also enabled the identification of rare inherited
variants with functional consequences that could contrib-
ute to the phenotype. As previously suggested, the joint
study of genomic and transcriptomic data can be crucial
to unravel the mechanism of complex diseases [77,78].
We detected alteration in expression levels in 1.7% of
expressed rare variants, inherited in all cases. Overexpres-
sion of MECP2 was found in a patient who had a rare
SNP variant in the same gene. Duplication of MECP2
causes a known duplication syndrome almost exclu-
sively in males with moderate to severe intellectual dis-
ability. Overexpression of the gene in peripheral
leucocytes was previously described in ASD patients
[79] and was also related to aggressive social behavior
in schizophrenia [80]. We also identified three rare mu-
tations with concurring overexpression of candidate
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[85] in a single patient. They were inherited from both
progenitors and they could contribute to ASD in an
additive manner. Additionally, we also detected mono-
allelic expression of the wild-type allele associated
with ten rare inherited truncating mutations suggest-
ing non-sense mediated decay (NMD) in which the
functional haploinsufficiency could contribute to the
phenotype such as the alteration in ALG9 [MIM
606941] and RIT1 [MIM 609591] previously involved
in neuropshychiatric conditions [86-88]. Finally, allele-
specific expression analysis revealed the alteration of 68
genes (or specific transcript variants) with monoallelic
expression but no cis-element responsible for it. This
phenomenon was found to be more common for auto-
somal and X-linked genes in ASD patients than in
controls in the brain and other tissues [89,90]. Allele-
specific expression can be caused by unidentified
cis-acting elements, including genetic or genomic
mutations in the promoter or regulatory regions and
epigenetic marks. Thus, some of identified genes with
allele-specific expression might contribute to ASD. In
fact, two of them have been previously associated
(MTOR) [91] and/or are great candidates (FUS and
TAF1C) [92,93]. Ongoing efforts to define the extent of
expression variation in large numbers of healthy
controls such as Geuvadis and GTEx will help to better
clarify the deregulated genes found in individual
patients that are related to disease.
Conclusions
In summary, our data reinforces the clinical utility of
NGS in establishing the cause of ASD. Although tran-
scriptome sequencing is limited by the genes
expressed in the analyzed tissue, it has proven to be
very useful in combination with WES. Their integra-
tion has determined the molecular defect compatible
with highly penetrant monogenic ASD forms in 19%
of the studied cohort. Blood transcriptomic data also
revealed functional correlations of genetic variants, in-
cluding changes in splicing, expression levels, and al-
lelic expression, as well as novel candidates with allelic
imbalance. Considering the likely multifactorial eti-
ology of most cases of ASD, data interpretation of the
potentially deleterious variation inherited from un-
affected progenitors still represents a challenge. Joint
analysis of transcriptome sequencing and deregulated
pathways by rare genetic variation can help to eluci-
date the genetic contribution of this complex disorder
and define deregulated mechanisms. The identification
of all genetic contributors in each patient will help to
establish genotype-phenotype correlations, define spe-
cific disorders, and identify pathophysiologic mecha-
nisms that can guide pharmacological approaches.Additional files
Additional file 1: Figure S1. Distribution of WES variants per patient
after filtering. Grey bars correspond to missense mutations, whereas red
bars correspond to LoF mutations. Figure S2. A) Pedigree of the family
ASD_16 compatible with X-linkage inheritance. B) Validation by Sanger
sequencing of the hemizygous MAOA splicing mutation (c.1438-2A > G)
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